Device Trial Radar · NCT05057117
Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis
Last checked: Nov 19, 2026Latest source record: May 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Sep 27, 2021
Primary completion
Oct 17, 2022
Study completion Apr 24, 2023
Sponsor
- Lead sponsor
- Merete HaedersdalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial aims is to assess and compare treatment effect of microwave thermolysis and botulinum toxin A for axillary hyperhidrosis with focus on longevity. The investigators also aim to assess patient satisfaction and adverse reactions in relation to treatment.
Conditions
- Hyperhidrosis Primary Focal Axilla
Interventions
Microwave thermolysisDevice
Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
Botulinum toxin ADrug
Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjective change in axillary sweatTime frame: Baseline - 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Dermatology, Bispebjerg Hospital
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.